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Abstract 
 
Objective: The purpose of this study was to assess the cost-effectiveness of an oral nutritional 
supplement program for patients with Chronic Obstructive Pulmonary Disorder (COPD) versus 
standard of care, which is no intervention in patient nutrition, from the perspective of a private 
payer in the United States. 
 
Methods: A probabilistic Markov Model was used to calculate total costs, quality adjusted life 
years, and number of exacerbations for a population of 500,000 COPD patients.  The two 
alternatives were standard of care and the use of an oral nutritional supplement twice a day for a 
year.  Cost estimates came from the literature and data from the Medical Expenditure Panel 
Survey, which was based on average reimbursement rates across the United States.  Quality of 
life scores and transition probabilities were based on data from the literature. 
 
Results: On average, the total cost of care for patients with oral nutritional supplements is lower 
than the standard of care.  The oral nutritional supplement program also resulted in fewer 
exacerbations and more QALYs.  The results estimate that the program can save $12,290/QALY 
gained for COPD patients. 
 
Conclusion: Results suggest that the oral nutritional supplement program is cost-saving for the 
COPD population and should be a serious consideration for insurance companies and health 
systems. 
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I. Research Objective 
COPD is an enormous and growing problem for the American healthcare system.  It is an 
expensive chronic condition and one that leaves patients unable to fully take care of themselves 
and perform regular daily tasks.  For COPD patients, an important part of how well they are able 
to live with the disease is what medications and services are covered by their health insurance. 
Using data from the literature and a Markov model, I assessed the balance of costs and benefits 
of providing COPD patients with oral nutritional supplements, specifically two nutritional 
supplements each day for a year. The key outputs that I examined for this modeling approach 
were total exacerbations, Quality Adjusted Life Years (QALYS), total cost, and incremental cost 
effectiveness ratio (ICER).  The goal of this research is to look at the cost effectiveness and 
possible quality of life and health impacts to determine if the coverage of non-traditional items 
such as nutritional supplements could make sense for insurance companies to cover as part of 
care plans.  This is particularly important as more and more people, especially seniors on 
Medicare Advantage plans and people on Medicaid managed care plans, are insured in capitated 
systems.  If these low cost solutions can make a difference it can mean better health for patients 
and more revenue for insurance companies, which could encourage insurance companies to pilot 
and offer more preventative and non-traditional programs for patients. 
II. Background 
COPD is a preventable, chronic progressive lung disease that is becoming increasingly 
important in healthcare because of the cost of treatment and the number of deaths resulting from 
the disease.  COPD is a rising cause of death in the United States and a disease that affects 6.3% 
of adults in the US -- about 24 million patients.  This rate may be an underestimate because 
many people do not know they have COPD and the disease often goes undiagnosed for a long 
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time.1 Patients with COPD are classified into different stages of the disease based on the COPD 
Global Initiative for Chronic Obstructive Lung Disease (COPD GOLD).  The stages, mild, 
moderate, severe, and very severe, are based on a patient’s ability to blow air out, which gives a 
good indication of air flow limitations.  More information on the staging can be seen in appendix 
item A.2  There are well established risk factors for COPD; according to the Mayo Clinic the 
most significant risk factors are "smoking, having asthma and smoking, occupational exposure to 
dust and chemicals, age, and genetics."3  The rate of COPD varies significantly across the United 
States, with many states in the Southeast having the highest prevalence.  This map shows COPD 
prevalence by congressional district and highlights the large discrepancies in COPD prevalence 
even within states.  
 
Image 1. COPD Prevalence by Congressional District4 
 
																																																						
1	(Centers	for	Disease	Control.)	
2	(WebMD)	
3	(Mayo	Clinic	Staff,	2015)	
4	(Centers	for	Disease	Control,	2014)	
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In addition to a high prevalence in the US, COPD is a growing problem globally.  With 
an aging global population, chronic diseases are becoming more common -- especially COPD.  
Around the world, smoking tobacco is a significant cause of COPD.  The World Health 
Organization estimates that "73% of COPD mortality is related to smoking, with 40% related to 
smoking in nations of low and middle income."5   The rates of COPD also vary by gender, which 
can be attributed to differences in smoking rates and the different types of jobs held by men and 
women.  The following chart shows the differences in COPD rates by gender for different 
countries. 
 
Image 2. Graph of COPD prevalence by gender globally6 
 
 
The cost of caring for patients with COPD from an insurance perspective is substantial; 
researchers found that the cost of the average patient with COPD is about $6000 more in medical 
costs than patients who were not diagnosed with COPD.7 The costs associated with COPD are 
mostly paid by government programs: in 2010 51% of the cost associated with COPD were paid 
																																																						
5	(Mannino	&	Buist,	2007)	
6	(Mannino	&	Buist,	2007)	
7	(Centers	for	Disease	Control)	
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by Medicare and 25% of the costs associated with COPD were paid by Medicaid.8 In addition to 
the direct healthcare costs paid for COPD related care, there are significant absenteeism costs 
from COPD, which greatly increase the disease’s burden on society; absenteeism costs in 2010 
were estimated to be about $3.9 billion.9 
One often overlooked side-effect that is highly correlated with COPD is malnutrition.  
The prevalence of malnutrition among patients with COPD ranges from 20% to 70% depending 
on patient demographics and comorbidities.  Malnutrition is an independent predictor of 
mortality for COPD patients and patients with lower weights have lower five-year survival 
rates.10 Patient with COPD lack energy to exercise and perform daily activities and begin to lose 
muscle and experience wasting especially in their extremities.  This can lead to reductions in 
body cell mass, the diaphragm, and respiratory muscles.  This further compounds the problem 
because the muscle loses result in even greater reduction in endurance and the ability to perform 
daily activities.11 A review of studies that examined Protein Energy Malnutrition (PEM) and 
chronic nonmalignant disorders found that in studies that focus on patients with COPD 
“nutritional treatment of PEM in connection with COPD may positively affect body composition 
as well as muscular strength and respiratory function.”12  
Insurance companies and other types of payers that take on risk based contracts feel the 
impact of the increasing COPD population and the high costs of their care.  COPD patients can 
be a very costly population for ACOs and managed care organizations.  Currently, few insurance 
companies or managed care organizations cover nutritional supplements for patients.  Some 
																																																						
8	(Centers	for	Disease	Control)	
9	(iv	Ford,	Murphy,	Khavjou,	Giles,	&	Holt,	2015)	
10	(Aknar,	2001)	
11	(Ezzell,	2000)	
12	(Aknar,	2001)	
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ACOs and managed care organizations are considering offering nutritional supplements to 
patients with COPD and protein energy malnutrition as a way of bringing down costs and 
helping to improve the lives and health of their patients. 
The concept of insurance companies covering non-traditional health related items is 
increasing in the United States.  In New York, the New York State commissioner of Health and 
the New York State Medicaid Director have both publicly argued for housing to count as 
healthcare for chronically homeless populations.  The argument they made was that the system 
would significantly save money in the long run by helping to pay for housing for these people.13  
This type of thinking is different from how healthcare and health insurance have traditionally 
operated where the providers would prescribe things but did not really think about what was 
happening outside of the walls of the doctor’s office or hospital.  Using modeling techniques to 
show the potential cost savings and impact of an oral nutritional supplement program could make 
a serious contribution to this current and relevant debate. 
 
III. Research Overview 
The connection between nutritional status and COPD outcomes is very apparent, but data 
about potential interventions that can benefit the patient and the payer is lacking.  In order to 
evaluate the possibility of using oral nutritional supplements to bring a patient back up to an 
energy level where they are able to better care for themselves and perform everyday activities, a 
Markov model, data from the literature, and probabilistic sensitivity analysis can be used to 
estimate important end points and outcomes.  Data was collected from various meta-analyses and 
research done in the COPD and nutrition fields.  The perspective of an payer was chosen as 
																																																						
13	(Aronczyk,	2014)	
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opposed to a global perspective because the implication of the research is to see if it could make 
sense for insurance companies both traditional, fee for service, healthcare insurers and managed 
care organizations, which have more of a population health approach already, to cover oral 
nutritional supplements for some of their COPD patients.  These results could have an impact on 
how insurance companies think about what they cover for patient care especially as the US 
healthcare system transitions over to more of a pay for performance model. 
 
IV. Specific Aims 
The first aim of the study is to determine if an oral outpatient nutritional supplement 
intervention reduces the cost of caring for COPD patients from the perspective of a payer.  My 
hypothesis is that the use of oral nutritional supplements will reduce the total cost of care at the 
one year end point. This end point was chosen because it is enough time to show substantial 
health changes. In addition, insurance companies and managed care organization often consider 
yearly costs and benefits. 
Using a Markov model and data from the literature, my second aim is to determine if a 
nutritional supplement improves quality of life of COPD patients.  Quality of life measures are 
closely connected to functional status of patients, so this measure can show an impact both in a 
patient’s ability to do daily activities and their overall health status.  In this study quality of life is 
measured in QALYS, with the QALY data coming from the literature.  My hypothesis is that the 
oral nutritional supplement intervention will, on average improve COPD patients’ QALYs. 
Using a Markov model and data from the literature, my third aim is to determine if a 
nutritional supplement intervention improves the number of total exacerbations for patients with 
COPD. Exacerbations, both severe and non-severe, are closely tied with inpatient hospital stays 
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and sharp spikes in the cost of caring for a patient with COPD. My hypothesis is that an oral 
nutritional supplement intervention reduces the number of exacerbations that a COPD patient 
experiences in a one-year time frame. 
 
V. Literature Review 
COPD Care Information 
The standard of care for COPD patients is put forward by the American Thoracic Society 
and the European Respiratory Society.  They recommend a step-wise treatment called the Global 
Initiative for Chronic Obstructive Lung Disease more commonly referred to as the GOLD 
treatment algorithm.  This treatment involves variations on a management program with the goal 
of slowing disease progression, addressing symptoms, improving health status and ability to 
exercise, and avoiding complications and exacerbations.14 
Nutritional Supplements and Chronic Disease 
Protein-energy malnutrition (PEM) is something that often occurs in connection with 
chronic diseases, including COPD.  One reason for this is that many chronic diseases impact the 
body’s metabolic functions and can cause decreased nutrient intake.  There is lots of research 
that established the relationship between patients with PEM and chronic disease and an increase 
in “morbidity, mortality, and extended hospital stays.”15 The causality between the treatment of 
PEM and improved symptoms for the chronic disease vary with both the chronic disease and the 
severity of the patient.  There has been a lot of research that looks into this connection especially 
among elderly populations.  One study published in the American Journal for Clinical Nutrition 
looked at the connection between PEM and COPD, chronic heart failure (CHF), stroke, 
																																																						
14	(Minkoff,	2005)	
15	(Aknar,	2001)	
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dementia, rehab following a hip fracture, chronic renal failure, rheumatoid arthritis, and other 
diseases that commonly impact the elderly.  A meta-analysis published in Clinical Nutrition 
Supplements in 2007 specifically looked at the use of oral nutritional supplements.  Disease-
related malnutrition increases mortality particularly for elderly patients in the hospital or those 
recently discharged from the hospital.16   
COPD and PEM 
A review of studies involving PEM and chronic diseases in the American Journal for 
Clinical Nutrition found 14 nutrition intervention trials specifically focused on COPD patients.  
Most of these were randomized control trials, but a few were observational trials.17  There is a 
large number of patients with PEM and COPD, but the estimates vary widely, from 20% to 70% 
of COPD patients.  The group that is most likely to have PEM among COPD patients is those 
that have COPD and emphysema.18  It takes a lot of effort for COPD patients to perform basic 
functions, so people with COPD frequently have an “imbalance between energy expenditure and 
dietary intake”.  This impact is further increased when patients experience exacerbations of their 
COPD.19  The problem compounds itself because as a patient losses lean body mass they often 
have reduced diaphragm mass, making it even harder for a patient with breathing issues to 
breathe.  Weight loss has been recognized as a problem for COPD patients for a long time.  Even 
in the 1970s it was seen that patients with COPD and weight loss had a significantly lower five 
year survival rate than patients with COPD alone.20  An examination of the observational and 
randomized control trials involving COPD and nutritional supplements in the review found the 
																																																						
16	(Stratton	&	Elias,	2007)	
17	(Stratton	&	Elias,	2007)	
18	(Aknar,	2001)	
19	(Aknar,	2001)	
20	(Vandenbergh,	van	de	Woestijine,	&	Gyelesen,	1967)	
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following: 9 of the 14 studies showed positive effects on body weight, 8 studies saw functional 
improvements, and 5 found both positive impacts on body weight and functional status.  Overall 
the review found that “nutritional treatment of PEM in connection with COPD may positively 
affect body composition as well as muscular strength and respiratory function.”21  A meta-
analysis specifically focused on oral nutritional supplements examined the efficacy in many 
different health conditions including COPD.  For the COPD trials the meta-analysis method 
found a significant weight change when patients used oral nutritional supplements as opposed to 
routine care.  The study also found that a weight gain of more than 2kg was correlated with 
improved functioning for the patient.22 
Modeling the issue 
Lots of research has been done on the clinical side using trials to identify the impact of 
nutritional supplements on patients with chronic diseases, especially COPD.  There have been 
fewer models to examine the impact of nutritional supplements on this population as a whole.  
One article published in Value in Health by Oosterbrink et al. used a probabilistic Markov model 
to look at COPD patients and what a change in their use and type of bronchodilators could do to 
change the number of exacerbations, QALYS, and total cost.  This study was done looking at 
patients in both the Netherlands and Canada, but the information can be applied to patients in the 
United States.  This probabilistic Markov model was created using data from clinical trials.  It 
had a one year end point and moved the populations through both baseline COPD health states 
and COPD exacerbations, which very accurately reflects how a COPD patient’s health status can 
change quickly.23  Another important COPD model that informed this research was also a 
																																																						
21	(Aknar,	2001)	
22	(Stratton	&	Elias,	2007)	
23	(Oosterbrink,	Rutten-van	Molken,	Monz,	&	Fitzgerald,	2005)	
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Markov model, but modeled the impact of home-based COPD management programs on patients 
from an economic perspective.  This study moved patients through health states in two different 
buckets: stable and unstable.  However the health states in this study did not correspond to the 
COPD GOLD stages that are commonly accepted in the treatment of COPD.  This study 
examined the possible impact of using a telehealth program to reduce the clinical and economic 
burden of patients with COPD.24 
Implementation 
There has been significant research done to look at the impact of nutritional supplements 
in improving the care of chronic disease patients.  Some of this research has caused action to be 
taken to implement policies to support the use of nutritional supplements.  Many of the studies in 
the meta-analysis by Stratton and Elia were used to help set and influence policies created by 
NICE and other European health organizations.25  For example, NICE now covers nutritional 
supplements for patients with malnutrition or who are at risk of becoming malnourished.  
However in the US, one of the major insurance companies, Aetna, only covers nutritional 
supplements provided by feeding tube or intravenously unless mandated by state law.  Other 
insurance companies do cover oral nutritional supplements, but adoption is not consistent or 
wide-spread. 
 
VI. Conceptual Model 
The overall idea is that patients with COPD lack the energy and nutrition necessary to perform 
daily activities and take care of themselves.  By adding an oral nutritional supplement, they are 
better able perform the activities to keep themselves healthy and out of the hospital.  Therefore 
																																																						
24	(Xin	Liu,	Lee,	Atakhorrymi,	&	al.,	2013)	
25	(Stratton	&	Elias,	2007)	
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the implementation of a regular use of oral nutritional supplements will reduce the probability of 
transitioning to a worse COPD GOLD stage from one month to the next.  See the image below 
for a diagram of the conceptual model for this research. 
 
Image 3. Conceptual Mod
 
 
 
VII. Research Methods 
Creation of Model 
A probabilistic Markov model was used to assess the impact of oral nutritional 
supplements in COPD patients.  This type of model was chosen because COPD patients do not 
pass from one health state to the next linearly, they can cycle back through different states.  For 
this reason a Markov model would more accurately match what happens to these patients than a 
decision tree or other types of models.  The model used was based off of the research done by 
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Oosterbrink et al. and published in Value in Health.  This model was chosen because of how it 
combined patients moving between health states and having exacerbations in those states.  The 
study also used published data and had good information about transition probabilities for the 
patients in the standard of care arm of the model.  This model served as a good base for creating 
a model to examine the impact of oral nutritional supplements on patients with COPD. 
 
Collecting Inputs 
The inputs in the model came from the literature and large public databases.  The 
transition probabilities for the current state model come from the standard of care portion of the 
Oosterbrink study.26  The modifications to the transition probabilities in the intervention model 
came from a meta-analysis of the effectiveness of nutritional supplements in patients with 
chronic diseases.27  This meta-analysis found a 1.53% increase in the probability of a patient 
improving, so for example in the intervention the probability of moving from the severe state to 
the moderate state was increased by that factor while the probability of moving from the severe 
state to the very severe state was decreased by that factor.  The transition probabilities for both 
the standard of care and intervention arm are shown in Table 1.  The population size for the 
model was based off of CDC estimates of the prevalence of COPD in North Carolina.  The cost 
estimates used information about inputs and health services usage from the Oosterbrink study 
and data from the Medical Expenditure Panel Survey (MEPS) database about the mean expenses 
per person for different services related to specific health states.  The cost of the supplement was 
from online information about the cost of buying the supplement Ensure in bulk.  Using the base 
Markov model and the MEPS data together it was possible to come up with estimates for the cost 
																																																						
26	(Oosterbrink,	Rutten-van	Molken,	Monz,	&	Fitzgerald,	2005)	
27	(Stratton	&	Elias,	2007)	
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of caring for COPD in the United States.28  These annual costs were divided into monthly costs 
to fit with the models time increments.  The QALY scores associated with the different health 
states and whether or not an exacerbation occurred were taken from the Oosterbrink study as 
well.  These QALY estimates were based on an observational study about the quality of life 
associated with the various COPD GOLD stages that was published in Value in Health.29 
 
Evaluating Outcomes 
The model and inputs resulted in point estimates of the impact of the outcomes of 
interest: exacerbations, QALYS, total cost, and Incremental Cost Effectiveness Ratio (ICER).  
Using Crystal Ball and either reported standard errors or a 20% range around an input, which 
was used for inputs that did not have reported variability, one thousand runs of the model were 
used to give a better understanding of the range of possible impact that could be expected if this 
intervention were to be implemented.  A one-way sensitivity analysis of certain key inputs was 
used to delve deeper into the impact of estimates that were deemed the most important using a 
tornado chart on select outcomes.  The tornado chart is included in the appendix. 
VIII. Description of Model and Inputs 
Model Design 
The probabilistic Markov model moves patient through three of the stages of COPD 
according to the COPD GOLD system: Moderate COPD, Severe COPD, and Severe COPD.  The 
model used as a basis for this research did not include a death state because of the very low 
number of deaths in the trials upon which they were basing their transition probabilities.  
Therefore the model for this research also excludes a death state in the model design.  In each 
																																																						
28	(Agency	for	Healthcare	Research	and	Quality)	
29	(Briggs,	Ericsson,	Wedzicha,	&	al.,	2004)	
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state, for every month patients have a chance of either having no exacerbation, a nonsevere 
exacerbation, or a severe exacerbation. A first short stage of 8 days is included in the model, this 
is because of an initial jump in energy that occurs with the beginning of starting an oral 
nutritional supplement in COPD patients who are often malnourished or who have protein 
calorie malnutrition.  See below for diagrams of both the model design and the conceptual 
model. 
Image 4. Model structure for Markov Model evaluating COPD 
 
 
Model Inputs 
The basis for the model inputs are described above in the research methods section.  The 
model inputs are from a combination of previously published articles and information from 
national survey data.  The inputs and their sources can be seen below in Table 1.  The estimate 
for the model population was based on the population of North Carolinians with COPD.  This 
was chosen so that the number would be useful if this data were to be presented to a large 
insurance company so they could envision the impact of the program on a large population.  The 
majority of the probabilities in the model are derived from the Oosterbrink study.  The transition 
probabilities indicate the probability of moving from one state to the next in a month.  The model 
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assumes that the individuals are in a given state for the full month.  Once the population has been 
assigned a given state for that month, then the probability of having an exacerbation is assigned 
to that subgroup.  The probability of exacerbation increases as the severity of COPD increases. 
 
Table 1. Probabilistic Markov Model Inputs 
 Input Source 
Model 
Population 
500,000 people (Centers for Disease Control.) 
Starting 
probability 
Moderate 
COPD 
25% (Oosterbrink, Rutten-van Molken, Monz, & Fitzgerald, 
2005) 
Starting 
probability 
Severe 
COPD 
50% (Oosterbrink, Rutten-van Molken, Monz, & Fitzgerald, 
2005) 
Starting 
Probability 
Very Severe 
COPD 
25% (Oosterbrink, Rutten-van Molken, Monz, & Fitzgerald, 
2005) 
 
Transition probabilities, per month (Standard of Care) 
 
(Oosterbrink, Rutten-van Molken, 
Monz, & Fitzgerald, 2005) 
From: To: Moderate Severe Very Severe 
Moderate 0.957 0.04 0.003 
Severe 0.023 0.954 0.023 
Very Severe 0.001 0.045 0.954 
 
Transition probabilities, per month (Intervention) 
(Oosterbrink, Rutten-van Molken, 
Monz, & Fitzgerald, 2005), 
(Stratton & Elias, 2007) 
From: To: Moderate Severe Very Severe 
Moderate 0.957 0.04 0.003 
Severe 0.0383 0.954 0.0077 
Very Severe 0.001 0.0603 0.9387 
Exacerbation probabilities, per month (Standard of 
Care and Intervention) 
 
(Oosterbrink, Rutten-van Molken, 
Monz, & Fitzgerald, 2005) 
 No Exacerbation Exacerbation Severe Exacerbation 
Moderate 0.852 0.051 0.097 
Severe 0.789 0.075 0.136 
Very Severe 0.712 0.096 0.192 
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The difference between the standard of care transition probabilities and the intervention 
probabilities are based on the information found in the meta-analysis by Stratton and Elias.  
The modification from the meta-analysis increases the probability of moving from Severe COPD 
to Moderate COPD and increases the probability of going from Very Severe to Severe.  So that 
the probabilities for each state still sum to 1, the increase in probability from severe to moderate 
is matched by a decrease in the probability of going from severe to very severe.  For the 
increased probability of moving from Very Severe to Severe the change is matched by a decrease 
in the probability of staying in the Very Severe state from one month to the next.  For example 
the probability of transitioning from severe to moderate in the standard of care state is 0.023 and 
in the intervention state it is increased to 0.0383. 
The other key estimates for the model are the cost estimates and QALYs for the various 
disease states.  The information for the cost data comes from the Oosterbrink study, the MEPS 
survey data, and estimates of the cost of providing nutritional supplements to each patient. 
 
Table 2. Cost estimates for the different COPD health states 
 
Estimated total cost of care per patient, per month 
(Standard of Care), units 2016 USD 
(Oosterbrink, Rutten-van 
Molken, Monz, & Fitzgerald, 
2005), (Agency for Healthcare 
Research and Quality) 
 No Exacerbation Exacerbation Severe Exacerbation 
Moderate $256.02 $449.21 $992.60 
Severe $2,514.49 $2707.67 $3251.07 
Very Severe $26,326.10 $26,519.27 $27,062.68 
 
Estimated total cost of care per patient, per month 
(Intervention), units 2016 USD 
**Standard of Care Cost + $71.70 Monthly Cost of program 
 
(Oosterbrink, Rutten-van 
Molken, Monz, & Fitzgerald, 
2005), (Agency for Healthcare 
Research and Quality) 
(Perkins, 2016) 
 No Exacerbation Exacerbation Severe Exacerbation 
Moderate $327.72 $520.91 $1064.30 
Severe $2,586.19 $2779.37 $3,322.77 
Very Severe $26,397.80 $26,590.98 $27,134.38 
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The moderate state with no exacerbation includes the cost of out-patient physician visits, 
prescription medications, and any services.  These three cost buckets match with the resource use 
described in the Oosterbrink study.  The cost for the Severe and Very Severe states with no 
exacerbation is scaled from the Moderate state estimate using cost information from the 
Oosterbrink study from the Netherlands.  So for example in the Netherlands the cost of severe 
COPD is 7.8 times the cost of moderate COPD.  This same factor was used to increase the cost 
of moderate COPD in the US to find an estimate of the cost of severe COPD in the US.  The base 
level costs between the US and the Netherlands were not comparable but the scale-up of services 
used as the disease state worsens can make for a useful comparable for estimating costs.  The 
same basic idea is used for estimating the cost of an exacerbation on top of the care needed 
without an exacerbation.  The services utilized for an exacerbation are hospital inpatient stay, ER 
visit, home health, and other services.  A Severe Exacerbation is assumed to cause a longer and 
more complicated hospital stay so the cost of a Severe Exacerbation is scaled up from an 
Exacerbation using the cost estimates from the Oosterbrink study.  The oral nutritional 
supplement program in this model is very scalable and just involves the cost of the supplement.  
The idea behind this is that the insurance company would ship a biweekly or monthly supply to 
patients in the program.  This puts the cost of the intervention at just the cost of two Ensure a day 
for a year per patient.  Most insurance companies already have the ability to ship prescriptions to 
patients so shipping Ensure would not need much increased capability to be shipped.  
The quality data comes from the Oosterbrink study as well.  This came more directly 
from the study because the quality adjusted life year scores are much more comparable from one 
country to another than cost data.  The QALY estimates in the Oosterbrink study came from an 
article published in Value in Health by Briggs et al.  In this study they used observation data to 
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come up with average QALY scores for the different COPD GOLD stages and then modified 
those scores for exacerbations and severe exacerbations.   
  
Table 3. QALY estimates for the different COPD health states 
Estimated QALY per patient, per month (Standard of Care 
and Intervention) 
(Oosterbrink, Rutten-van Molken, 
Monz, & Fitzgerald, 2005), 
(Briggs, Ericsson, Wedzicha, & 
al., 2004) 
 No Exacerbation Exacerbation Severe Exacerbation 
Moderate 0.755 0.64175 0.3775 
Severe 0.748 0.6358 0.374 
Very Severe 0.549 0.4667 0.2745 
 
The associated quality of life scores indicate a large drop off in quality of life if a patient 
moves from the Severe stage of COPD to the Very Severe.  There is only a 0.007 difference in 
QALYs if a patient moves from the Moderate COPD health state to the Severe COPD health 
state.  This difference seems very small when using quality adjusted life years as a measure, but 
comes out to about 2.52 days per patient, which with a large patient population can make a large 
difference.  There is also a sharp decrease in QALYs if a patient has a severe exacerbation versus 
just a regular exacerbation.  Severe exacerbations generally mean more hospital time, a longer 
recovery, and much higher chance of complications.  An ICER for QALYs was measured by 
determining the differential Total Cost for the model and the incremental total QALY score.  The 
incremental total cost was divided by the incremental QALY score to find the ICER for QALYs. 
IX. Results 
Base Case 
In the base case resulted in relevant and impactful data.  The base case results are shown 
below in Table 4.  The outputs of interest for this model were total cost, number of exacerbations 
in total and for the two subcategories of exacerbations and severe exacerbations, total Quality 
Adjusted Life Years, and the Incremental Cost Effectiveness Ratio.  In the base case of this 
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model, using the inputs in the previous tables the model found cost savings, reduced 
exacerbations, and increased quality adjusted life years.  This means that the intervention would 
have a negative ICER indicating that implementing this strategy would both save money for 
whoever is paying for the healthcare costs and result in a better quality of life and less time in the 
hospital for the patients. 
 
Table 4. Base Case Results from Probabilistic Markov Model 
COPD Population at Risk 
   Exacerbations    
Alternative Total Costs Inc. Costs Nonsevere 
Exacerbations 
Severe 
Exacerbations 
Total 
QALYs 
Inc. 
QALYs 
ICER 
(QALYs) 
Standard of 
Care 
$26,170,636,685  445,236 841,531 3,864,151   
Nutritional 
Supplement 
$24,337,962,688 - $1,832,673,997 
 
414,079 776,502 4,013,261 149,110 -$12,290 
 
Sensitivity Analysis 
While the base case results for the model are very promising, it is important to remember 
that they are based off of estimates with some uncertainty.  For this reason it is important to 
apply sensitivity analysis to the model.  This model contained a lot of different estimates and 
transition probabilities, so a probabilistic sensitivity analysis allows for changing all of the 
probabilities at once.  This gives a better understanding of the range of possible impacts that a 
oral nutritional supplement program could have as opposed to just making decisions off of the 
base case.  The Oosterbrink article that the transition probabilities and QALY data came from 
gave both point estimates and standard errors for these probabilities.   Using this information a 
triangle distribution was applied to all of probabilities.  A triangle distribution was chosen 
because some of the probabilities were either very close to 1 or very close to 0 and this allowed 
for the range of the probability to be capped at the logical bounds.  For the triangle distributions 
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the most likely value was the point estimate and the minimum and maximum were three standard 
errors above or below that, unless that would give a number outside of the 0 to 1 range in which 
case a cap of 0 or 1 was used.  The minimum and maximum for the cost estimates were 20% 
above or below the point estimate.   
The probabilistic sensitivity analysis was performed using the Crystal Ball software.  
This analysis produced similar results to the base case, with the intervention generally resulting 
in lower costs, higher QALYs, and fewer exacerbations.  These results can be seen in the charts 
included in Appendix B.  There is a noticeable difference between the standard of care and 
intervention for both total cost and QALYs, with lower cost and higher QALYs for the 
intervention arm.  The difference between the total exacerbations for the standard of care and 
intervention arms of the model are the most distinct with two separate peaks for the two charts.  
This chart is available in Appendix B. 
 
Image 5. ICER Plane for Total Cost and QALYs from probabilistic Markov Model 
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Another important output of the probabilistic sensitivity analysis is the Incremental Cost 
effectiveness ratio.  To show the possible ICER’s for the oral nutritional supplement 
intervention, Crystal Ball was used to create an ICER plane.  In the ICER plane, the y-axis is the 
difference in total cost between the standard of care arm and the intervention arm.  A negative 
cost difference costs were lower for the intervention arm than the standard of care arm.  The x-
axis is the difference between QALYs for the two arms of the model.  An ICER plane is useful 
for thinking about how to make the decision to implement a new program.  If most of the 
outcomes are in the top left quadrant than the program results in higher cost and lower QALYs 
and is a dominated strategy that is likely a poor idea to implement.  The bottom left and top right 
quadrants are interventions that would require a tradeoff, so either higher cost but more QALYs 
or lower cost but few QALYs.  The bottom right chart is where most of the runs for the model 
were located for this Markov Model.  This means that in 92% of cases this model predicts that 
implementing the oral nutritional supplement program would cause lower costs and increased 
QALYs. 
 
X. Discussion 
The outcomes from this model are encouraging because they show the potential for low cost 
interventions to have a significant impact on patient health.  The sensitivity analysis is critical 
because the estimates of transition probabilities and cost may vary based on location, population, 
and many other factors.  The sensitivity analysis shows that while, for the most part, this 
program results in better quality of life and cost savings, there is a wide range of possible health 
outcomes and total costs.  According to the sensitivity analysis 92% of runs were cost saving and 
quality improving and 8% of runs were cost saving but did not improve quality of life.  Further 
	 	 	
	
	 	 	
	
23	
research could be done to modify the transition probabilities and other estimates based on 
comorbidities.  COPD patients often have other chronic diseases so being able to predict the 
impact of the intervention on a specific subset of the patient population.  These modifications 
could also be key to convincing insurance companies to cover oral nutritional supplements for 
more groups of COPD patients.   
The outputs from the model and sensitivity analysis are very useful for looking at the 
possible impact of covering supplements for patients.  It is important to combine this information 
with knowledge of the industry and how coverage decisions are made and how similar programs 
have performed to understand the likelihood of an organization being willing to invest in and 
implement this type of a program.  It is also critical to consider things like the logistics of 
running this type of program and how likely patients are to stick to a twice a day oral nutritional 
supplement regimen.  This assessment is important for making recommendations and which 
types of insurance companies or healthcare organizations to push to use this type of intervention.  
The results from this model show that there is significant potential in the use of low cost 
nutritional supplement interventions to improve care for patients with COPD, but further 
research and investigation is likely needed. 
XI. Limitations 
This model has some important limitations and areas where more information would 
improve the model and its predictive capabilities.  One key limitation is the patient adherence to 
the program over an entire year is likely to be much lower than 100%, the impact factor used 
from the meta-analysis did not have information about how adherence would modify the impact.  
The adherence problem is particularly important because oral nutritional supplements like 
Ensure are commonly complained about by patients because of the taste.  If a patient does not 
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like the taste they are much less likely to have high adherence to the regimen.  Better cost data 
specific to a certain population or area would be useful in order to create a more robust and 
meaningful model.  The cost information is very high level and more precise micro-costing could 
give a better estimate.  The cost information for the Ensure supplement excludes shipping costs.  
There is likely a cost to this but it is ultimately much smaller than the cost savings found and so 
would not be consequential if included in the model.  Using insurance claims data, possibly even 
broken down for distinct areas, could give a more accurate cost estimate.  This could be 
important to include because COPD prevalence in the United States is very high in some rural 
areas.  Another important limitation is that the model does not include possible negative effects 
of using oral nutritional supplements such as nausea and vomiting.  This could be important to 
know because it may be better to only enroll patients in the oral nutritional supplement program 
if they are in the worse COPD GOLD stages because of the possibility for side effects and low 
adherence.  Despite some important limitations, this study has some important findings that can 
inform the discussion about possible ways to care for patients with COPD. 
XII. Implications 
The findings from this model have interesting implications for both the current state of 
healthcare in the United States and where the trends in healthcare are going.  In its current form, 
the two best types of organizations for adopting a program like the proposed oral nutritional 
supplement program are managed care organizations or hospitals/health systems that have taken 
on risk-based population health contracts.  These types of organizations tend to have a better line 
of communication with the physicians, have an incentive structure that aligns with the ideas of 
the program, and are often focused on the Medicare population where COPD is very common.  
An oral nutritional supplement program could also be implemented on a smaller scale by 
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hospitals.  Instead of giving the supplements to a larger group, hospitals could offer the program 
to COPD patients who are frequent visitors to the Emergency Department as a way to reduce the 
number of costly ED visits those patients have in a year.  As the US healthcare system transitions 
to more of a fee-for-performance system, this type of program should become more common and 
embraced by insurance companies and health systems. 
 
XIII. Conclusion 
Preliminary results reveal that an oral nutritional supplement program for patients with 
COPD can result in total cost savings for caring for the population and improved quality of life 
measures.  On a per patient basis, the intervention results in approximately $3,665 in savings per 
year and 0.298 more QALYs, which is equivalent to 108 days.  The goal for this evaluation was 
to show the potential impact of creating and implementing low cost interventions for patients 
with chronic diseases like COPD that can keep them feeling healthier and out of the hospital.  
From a business perspective this is also compelling evidence for an insurance company or 
managed care organization that an investment in a program like this can result in significant 
savings.  This is particularly important because of the growth of the COPD population in the 
United States and around the world.  Based on the results, we recommend futher research into 
the potential uses of oral nutritional supplements and other ways to improve patient nutrition as 
well as research to better understand how to create interventions for patients with multiple 
chronic diseases. 
 
 
 
	 	 	
	
	 	 	
	
26	
Acknowledgements 
Finally, I would like to thank the following people without whom this project would not 
have been possible: Justin Trogdon, PhD (First Reader); Kristen Hassmiller Lich, PhD (Second 
Reader); Elvin Perkins (Unofficial Advisor); Morris Weinberger, PhD (Master’s Thesis Seminar 
Leader); and Bruce Fried, PhD (Master’s Thesis Seminar Leader).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 	 	
	
	 	 	
	
27	
Appendix. 
Appendix A. COPD GOLD staging criteria 
 
Stage I Mild COPD FEV1/FVC<0.70 FEV1≥ 80% normal 
Stage II Moderate COPD FEV1/FVC<0.70 FEV1 50-79% normal 
Stage III Severe COPD FEV1/FVC<0.70 FEV1 30-49% normal 
Stage IV Very Severe COPD FEV1/FVC<0.70 FEV1 <30% normal, or <50% normal 
with chronic respiratory failure 
present* 
• Usually, this means requiring long-term oxygen therapy. 
 
Appendix B. Probabilistic Sensitivity Analysis of Total Cost of Care, QALYs, and Total 
Exacerbations 
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**In this chart “Home Health” refers to the cost bucket of home health services for patients 
recovering from an exacerbation.  The “Modification factor” is the amount that the transition 
probabilities are changed by in the intervention branch of the model. 
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